ATOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Atossa Therapeutics Inc (ATOS) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak financial performance, limited positive catalysts, and lacks strong technical or trading signals. While analysts maintain a Buy rating with high price targets, the company's ongoing profitability challenges and lack of significant growth trends make it a risky investment.
The MACD is slightly positive but contracting, RSI is neutral at 33.304, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 4.766, with resistance at 5.874. Overall, the technical indicators do not suggest a strong buying opportunity.
FDA designations for (Z)-endoxifen therapy and ongoing breast cancer studies (I-SPY and EVANGELINE) could provide long-term potential if successful.
The company reported a significant net loss of $34.8 million for 2025, with operating expenses increasing by 34.5%. The FY GAAP EPS of -$4.04 missed expectations, and the stock price dropped 13.10% in regular trading. No recent insider or hedge fund buying activity was noted.
The company's financials for Q4 2025 showed no revenue growth, a net income loss of -$10.937 million, and an EPS of -60.57, indicating severe profitability challenges. Operating expenses increased significantly due to rising R&D costs.
Analysts maintain a Buy rating with price targets adjusted to $25 and $10, citing potential in ongoing breast cancer studies. However, the pause in Z-endoxifen's development for metastatic breast cancer and the company's limited cash runway are concerns.
